Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05043987
Other study ID # CPO102-US-1001
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date November 16, 2022
Est. completion date November 16, 2022

Study information

Verified date September 2023
Source Conjupro Biotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available.


Description:

This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available. All patients must have failed standard first or later lines of systemic therapy. The study design overview is presented below. The study will consist of 2 parts, Part A and Part B. Part A will explore once every 3 weeks (Q3W) dosing per standard 3+3 dose escalation design. Upon attaining a RP2D, Part B will commence in 2 groups, in approximately 15 patients with advanced pancreatic cancer and 15 patients with advanced gastric including gastric esophageal junction cancers. Part B will seek to confirm the RP2D and will also seek early signals of efficacy in the selected cancer patient populations.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 16, 2022
Est. primary completion date November 16, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Applicable to all patients in both Part A and Part B of the study: - Pathological diagnosis (histological) of pancreatic or gastric including esophageal junction cancers. - Patient must provide archived tissue block or formalin-fixed paraffin-embedded (FFPE) slides or fresh biopsy prior to start of treatment. - Positive claudin 18.2 tumor expression defined as =50% of tumor cells demonstrating moderate-to-strong membranous staining (2+/3+) by IHC assay performed on sections of tumor derived from formalin fixed paraffin block. - Adequate organ function. - Life expectancy >12 weeks. - Age =18 years. - ECOG performance status 0 or 1 at screening. - Ability to understand the nature of this study, comply with protocol requirements, and give written informed consent. - Patients of reproductive potential: All female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before study entry. Specific criteria for Part A: - Disease progression or relapse following conventional chemotherapy: 1. Pancreatic cancer 2. Gastric cancer (including GEJ cancer) Specific criteria for Part B: - Measurable disease suitable for imaging and efficacy tracking as defined by RECIST 1.1 - Disease progression or relapse following conventional chemotherapy: 1. Pancreatic cancer 2. Gastric cancer (including GEJ cancer) Exclusion Criteria: 1. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to baseline or to common terminology criteria for adverse events (CTCAE) grade =1, with the exception of alopecia, =grade 2 neuropathy, or to the levels dictated in the inclusion/exclusion criteria. 2. Patient has participated in any investigational research study and is being screened for participation within a period of 5 half-lives or 4 weeks, whichever is longer, of the last dose of the investigational therapy. 3. History of severe infusion reaction with monoclonal antibody treatment. 4. Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening. 5. HIV positive test within 8 weeks of screening. 6. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment. 7. Presence of other active cancers, or history of treatment for invasive cancer =3 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, noninvasive) are eligible, as are patients with history of nonmelanoma skin cancer. 8. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol. 9. Active central nervous system (CNS) disease involvement, defined by cerebrospinal fluid (CSF) cytology, magnetic resonance imaging (MRI) or computerized tomography (CT); patients with asymptomatic CNS metastases are eligible if participants have been clinically stable for at least 4 weeks prior to the first dose of study drug and do not require interventions such as surgery, radiation or any corticosteroid therapy for management of symptoms related to CNS disease. 10. Peripheral neuropathy Grades = 2. 11. Active ocular surface disease at baseline (based on ophthalmic evaluation). 12. Pregnant or nursing (lactating) women. 13. Patients who received claudin 18.2 targeting agents previously. 14. Patients who have received or will receive coronavirus disease 2019 (COVID-19) vaccine within 72 hours prior to the first dose of study drug. 15. Prior radiotherapy

Study Design


Intervention

Drug:
CPO102
Anti-claudin 18.2 Antibody-MMAE Drug Conjugate

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Conjupro Biotherapeutics, Inc. CSPC Megalith Biopharmaceutical Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with dose-limiting toxicities (DLTs) during the DLT evaluation period. DLTs are assessed during the first cycle (21 days) in each cohort to determine maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). through study completion, an average of 3 year
Secondary Number of participants with treatment-emergent adverse events (TEAEs) including Grade = 3, serious, fatal TEAE by relationship. TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0. through study completion, an average of 3 year
Secondary Number of participants with clinically significant changes in vital signs Number of participants with clinically significant changes in vital signs through study completion, an average of 3 year
Secondary Number of participants with clinically significant changes in clinical laboratory tests Number of participants with clinically significant changes in clinical laboratory tests through study completion, an average of 3 year
Secondary CPO102 pharmacokinetics: Area under the concentration time curve over the dosing interval. CPO102 pharmacokinetics: Area under the concentration time curve over the dosing interval. through study completion, an average of 3 year
Secondary CPO102 pharmacokinetics: Maximum concentration of the drug (Cmax) CPO102 pharmacokinetics: Maximum concentration of the drug (Cmax) through study completion, an average of 3 year
Secondary CPO102 pharmacokinetics: Time to maximum concentration (Tmax) CPO102 pharmacokinetics: Time to maximum concentration (Tmax) through study completion, an average of 3 year
Secondary CPO102 pharmacokinetics: Elimination half-life (t1/2) CPO102 pharmacokinetics: Elimination half-life (t1/2) through study completion, an average of 3 year
Secondary CPO102 pharmacokinetics: Clearance (CL) CPO102 pharmacokinetics: Clearance (CL) through study completion, an average of 3 year
Secondary CPO102 Objective response rate (ORR) ORR is defined as the proportion of patients in whom a complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 is observed as best overall response. through study completion, an average of 3 year
Secondary CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA) CPO102 immunogenicity: Number of participants with anti-drug-antibody (ADA) through study completion, an average of 3 year
See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study